Alloga Uk Limited

Alloga UK Limited is a specialized logistics provider focusing on third-party logistics and warehousing solutions for the pharmaceutical and healthcare sectors. The company aims to enhance patient access to medications through its comprehensive service offerings. Alloga UK Limited, founded in 1996, operates as a third-party logistics provider dedicated to the pharmaceutical and healthcare industries. The company has its headquarters in the UK and specializes in logistics and warehousing services.

There are no recorded pivots in business strategy or notable changes in operations. As of now, there is no information available on its founders or CEO. Alloga UK Limited specializes in providing comprehensive third-party logistics (3PL) and warehousing solutions tailored specifically for the pharmaceutical and healthcare sectors. Their core service offerings include logistics and warehousing, drug research and clinical development support, commercialization assistance, and patient access solutions.

By leveraging a global network, the company ensures safe storage and timely delivery of pharmaceutical products. Their client base comprises pharmaceutical manufacturers, biopharma companies, healthcare providers, and pharmacies, all utilizing Alloga's services to streamline operations and improve patient outcomes. The company operates across diverse geographical markets, including the United States, Canada, Europe, and Australia. Alloga UK Limited's revenue model is built on a framework of B2B transactions, primarily engaging with pharmaceutical manufacturers and healthcare providers through contracts and partnerships.

The company facilitates the distribution and logistics of pharmaceutical products, employing fixed pricing for storage and delivery services, alongside variable costs linked to specific service levels or volumes of products handled. Their business operations include agreements with wholesalers and direct-to-consumer retailers, ensuring a seamless supply chain from manufacturers to end-users. Key service offerings, such as biosimilar distribution and integrated support for biopharma companies, are expected to significantly contribute to their revenue streams as the demand for specialized logistics within the industry grows. Currently, there is no publicly available information regarding upcoming new products, market expansion plans, or the utilization of recent funding.

The company's strategy for future growth and any targeted markets or regions remains unspecified.